Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane: Results from a multicenter phase I/II study

Cancer

Volumn 103, Issue 7, 2005, Pages 1388-1396

  Gronlund, Bo ^a   Engelholm, Svend A ^a   Horvath, György ^b   Mäenpää, Johanna ^c   Ridderheim, Mona ^d  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Etoposide; Ovarian neoplasms; Phase I; Recurrence; Response; Second line treatment; Topoisomerase inhibitor; Topotecan

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; CREATININE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; HEMOGLOBIN; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ECHOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM; TAXOIDS; TOPOTECAN;

EID: 15744403993     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20921     Document Type: Article

References (27)

1. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161-1163.
2. Deppe G, Baumann P. Advances in ovarian cancer chemotherapy. Curr Opin Oncol. 2000; 12:481-491.
3. Vasey PA, Kaye SB. Combined inhibition of topoisomerases I and II-is this a worthwhile/feasible strategy? Br J Cancer. 1997;76:1395-1397.
4. Herzog TJ. Clinical experience with topotecan in relapsed ovarian cancer. Gynecol Oncol. 2003;90:S3-S7.
5. Pizzolato JF, Saltz LB. The camptothecins. Lancet. 2003;361: 2235-2242.
6. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol. 1995;6:325-341.
7. Eckhardt S, Hernadi Z, Thurzo L, et al. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) study. Oncology. 1990; 47:289-295.
8. Kuhn W, Schmalfeldt B, Dose J, et al. [Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study.] Geburtshilfe Frauenheilkd. 1996;56:105-110.
9. Crump M, Lipton J, Hedley D, et al. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group study. Leukemia. 1999;13:343-347.
10. Huisman C, Postmus PE, Giaccone G, Smit EF. A Phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. Ann Oncol. 2001;12:1567-1573.
11. National Cancer Institute. Guidelines for reporting adverse reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute, 1998.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
14. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-760.
15. Hammond LA, Eckardt JR, Ganapathi R, et al. A Phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res. 1998;4:1459-1467.
16. Herben VM, Bokkel Huinink WW, Dubbelman AC, et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer. 1997;76: 1500-1508.
17. Mok TS, Wong H, Zee B, et al. A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer. 2002;95:1511-1519.
18. Desoize B, Woirin V, Legros M, Coninx P. Reduced oral etoposide bioavailability in patients with advanced cancer of the head and neck. J Natl Cancer Inst. 1992;84:348-350.
19. Gronlund B, Hansen HH, Hogdall C, Engelholm SA. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer. 2002;95:1656-1662.
20. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410.
21. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001;83:257-262.
22. Rose PG, Rodriguez M, Walker J, Greer B, Fusco N, McGuire W. A Phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2002;85: 136-139.
23. van der Burg ME, de Wit R, van Putten WL, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer. 2002;86:19-25.
24. Guastalla JP, Ferrero JM, Benbunan JL, et al. Topotecan (T) followed by etoposide (E) in pretreated ovarian cancer (OC) patients - a GINECO Phase II study [abstract 320]. Ann. Oncol. 1998. Available from URL: http://www.esmo.org/ reference/abstracts/gc/320.htm [accessed 8 February 2005].
25. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol. 1997;8:963-968.
26. Aravantinos G, Dimopoulos MA, Kosmidis P, et al. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Ann Oncol. 2000;11:607-612.
27. Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol. 2001;12:1705-1709.